B. Kantesaria

发表

Pharmacokinetics/Pharmacodynamics of Desloratadine and Fluoxetine in Healthy Volunteers

Samir K. Gupta, C. Banfield, B. Flannery, 2004, Journal of clinical pharmacology.

Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.

R. Clement, C. Banfield, M. Affrime, 2001, Clinical therapeutics.

Evaluation of the exposure equivalence of oral versus intravenous temozolomide

M. Cantillon, D. Cutler, P. Statkevich, 2009, Cancer Chemotherapy and Pharmacology.

Insulin glargine and its two active metabolites: A sensitive (16pM) and robust simultaneous hybrid assay coupling immunoaffinity purification with LC-MS/MS to support biosimilar clinical studies.

K. Bateman, E. Woolf, Li Sun, 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men

G. Krishna, T. Mant, B. Kantesaria, 2007, Current medical research and opinion.

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease

D. Cutler, T. Kosoglou, F. Xuan, 2013, International journal of chronic obstructive pulmonary disease.

Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects

J. Butterton, J. McCrea, M. Iwamoto, 2018, Journal of clinical pharmacology.

An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered‐dose inhaler versus an MF dry‐powder inhaler in healthy subjects

D. Cutler, T. Kosoglou, M. Hanson, 2014, Clinical pharmacology in drug development.

Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety

Samir K. Gupta, Zaiqi Wang, B. Prenner, 2006, Expert opinion on drug safety.

Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.

S. Miller, D. Cutler, T. Kosoglou, 2013, Chest.

Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection

G. Krishna, M. Martinho, B. Kantesaria, 2007, Antimicrobial Agents and Chemotherapy.

Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men

G. Krishna, B. Kantesaria, Angela Sansone-Parsons, 2007, Current medical research and opinion.

Effects of Age, Gender, and Race/Ethnicity on the Pharmacokinetics of Posaconazole in Healthy Volunteers (cid:1)

J. Simon, G. Krishna, R. Stoltz, 2007 .

Effects of Age, Gender, and Race/Ethnicity on the Pharmacokinetics of Posaconazole in Healthy Volunteers

J. Simon, G. Krishna, R. Stoltz, 2006, Antimicrobial Agents and Chemotherapy.

Simplification of Imipenem Dosing by Removal of Weight‐Based Adjustments

M. Rizk, Mallika Lala, M. Brown, 2018, Journal of clinical pharmacology.

Effect of a Nutritional Supplement on Posaconazole Pharmacokinetics following Oral Administration to Healthy Volunteers

G. Krishna, B. Kantesaria, Mitchell Rosenberg, 2006, Antimicrobial Agents and Chemotherapy.

Effect of Oral Posaconazole on the Pharmacokinetics of Cyclosporine and Tacrolimus

S. Gelone, G. Krishna, M. Martinho, 2007, Pharmacotherapy.

Validation of a sensitive and automated 96-well solid-phase extraction liquid chromatography-tandem mass spectrometry method for the determination of desloratadine and 3-hydroxydesloratadine in human plasma.

Robert Masse, Liyu Yang, Robert P Clement, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies

G. Shapiro, M. Mita, Da Zhang, 2012, Cancer Chemotherapy and Pharmacology.

Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults.

Samir K. Gupta, Zaiqi Wang, C. Banfield, 2007, British journal of clinical pharmacology.

Bioavailability and Metabolism of Mometasone Furoate following Administration by Metered‐Dose and Dry‐Powder Inhalers in Healthy Human Volunteers

M. Cayen, R. Clement, M. Affrime, 2000, Journal of clinical pharmacology.

Vorapaxar, an oral PAR‐1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone

T. Kosoglou, P. Statkevich, M. Hanson, 2015, Clinical pharmacology in drug development.

Pharmacokinetics of desloratadine in children between 2 and 11 years of age.

Samir K. Gupta, C. Banfield, B. Kantesaria, 2007, British journal of clinical pharmacology.

Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing.

P. Glue, B. Kantesaria, S. K Gupta, 2014, Drug discoveries & therapeutics.

Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment.

Samir K. Gupta, P. Glue, B. Kantesaria, 2013, Drug discoveries & therapeutics.

No drug interaction between fluoxetine and desloratadine, a new nonsedating once-daily antihistamine

Samir K. Gupta, M. Cayen, C. Banfield, 2001 .

A Model-Based Approach to Bridging Plasma and Dried Blood Spot Concentration Data for Phase 3 Verubecestat Trials

E. Woolf, J. Stone, D. Jaworowicz, 2022, The AAPS Journal.